Oncology

Artificial intelligence shows promise in improving diagnosis and treatment for patients with multiple myeloma.

Early diagnosis of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) may mitigate progression.

Automation and artificial intelligence can also aid significantly in reducing time-consuming tasks and improving efficiency for pharmacists, allowing them more time with patients.

Although Madabhushi said there are emerging tools for clinical decision support, he said there is a greater need for tools further downstream in the post-diagnosis stages.

However, early diagnosis still presents challenges and limits treatment options.

About 72% of the observed pregnancies after allogeneic hematopoietic cell transplantation occurred spontaneously, whereas remaining pregnancies were a result of assisted reproductive activities.

Compared with chemotherapy, datopotamab deruxtecan (Dato-DXd) did not achieve a statistically significant overall survival (OS) in patients with inoperable or metastatic HR+/HER2-low or negative breast cancer.

The meeting will focus on the basic, preclinical, and clinical aspects of myeloma, including precursor disease, high-risk disease, immunotherapies, novel biomarkers, and more.

William Carroll, PharmD, network vice president of pharmacy at Hackensack Meridian Health, discusses his hopes for the new partnership.

The decision expands treatment options for patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM).

Ponsegromab displayed significant and robust increases in body weight at the completion of the study for all doses.

Shifting from a vertical, isolated care model into a collaborative approach can improve the clinician and patient experience.

The CRAFT (NCT04551521) trial is still ongoing to assess findings in the remaining patient arms.

Improvements in survival outcomes were seen among those at high risk for DLBCL who received 6x R-CHOP21 + 2R.

Amivatamab-vmjw is a fully-human bispecific antibody targeting EGFR and MET with immune cell-directed activity.

Using ultrasound and clinicopathological characteristics, the studied nomograms effectively evaluated recurrence risk in HR-/HER2+ and HR+/HER2+ breast cancer.

Patients with for HER2-positive breast cancer have an increased risk of developing brain tumors.

Pembrolizumab is an anti-programmed death receptor 1 (PD-1) therapy designed to increase the immune system’s ability to detect and fight tumor cells.

The combination of amivantamab and lazertinib showed improved intracranial efficacy, progression-free survival, and overall survival for non-small cell lung cancer.

The humanized anti-butyrophilin 3A monoclonal antibody selectively activates Vγ9Vδ2 T-cells.

In 2 studies, durvalumab improved overall survival for those with unresectable hepatocellular carcinoma and event-free survival for muscle-invasive bladder cancer.

The approval is based on positive results from the phase 2/3 IND.227/KEYNOTE-483 trial.

The treatment significantly reduced risk of occurrence by 25% compared with endocrine therapy alone.

Ten-year follow up data showed a sustained survival benefit with nivolumab-ipilimumab in advanced melanoma.

In 2021, cancer diagnosis rates remained low after major disruptions during the first year of the COVID-19 pandemic.

The trial demonstrated that the combination of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) significantly improves progression-free survival and objective response rates compared to TACE alone.

The efficacy and safety profiles of CAR T-cell and bispecific antibody therapies have led to their investigation in earlier lines of therapy, with several new treatments in development.

Data from the second interim analysis of the DETECT V trial, presented at ESMO Congress 2024, suggest that a chemotherapy-free regimen combining dual HER2-targeted therapy with endocrine therapy, particularly with the addition of ribociclib, may be an effective treatment for patients.

Abstracts from the OrigAMI-1 and MARIPOSA-2 trials indicated the treatment benefits of amivantamab-vmjw and chemotherapy in multiple cancer indications.

At ESMO Congress 2024, Shuji Ogino, MD, PhD, MS, explained that the rising incidence of young-onset cancer may be due to generational risk factors such as lifestyle, diet, and environmental changes, emphasizing the need for long-term research and follow up to understand early-life influences on cancer development.